What factors influence BTKi + BCL-2i treatment selection for patients with CLL?
The Lymphoma Hub was pleased to speak to Francesc Bosch, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES. We asked, what factors influence Bruton’s tyrosine kinase inhibitor (BTKi) + B-cell lym...
5 Marras 20257min
Latest updates from the phase III STARGLO trial: 2L and 3L+ data
The Lymphoma Hub was pleased to speak to Charles Herbaux, University of Montpellier, FR. Herbaux discussed the latest updates from the phase III STARGLO trial (NCT04408638), with a focus on second-lin...
15 Loka 20253min
Symposium | Customizing therapy for MCL: Q&A
During the 18th International Conference on Malignant Lymphoma (ICML), June 17–21, 2025, Lugano, CH, the Lymphoma Hub held a symposium on June 17, 2025, titled Customizing therapy for mantle cell lymp...
4 Syys 20258min
Symposium | Current therapies for MCL and their combinations
During the 18th International Conference on Malignant Lymphoma (ICML), June 17–21, 2025, Lugano, CH, the Lymphoma Hub held a symposium on June 17, 2025, titled Customizing therapy for mantle cell lymp...
3 Syys 202528min
Symposium | Sequencing therapies and practical management of adverse events in MCL
During the 18th International Conference on Malignant Lymphoma (ICML), June 17–21, 2025, Lugano, CH, the Lymphoma Hub held a symposium on June 17, 2025, titled Customizing therapy for mantle cell lymp...
19 Elo 202523min
Symposium | Unmet needs in the treatment of MCL
During the 18th International Conference on Malignant Lymphoma (ICML), Jun 17–21, 2025, Lugano, CH, the Lymphoma Hub held a symposium on June 17, 2025, titled Customizing therapy for mantle cell lymph...
17 Heinä 202516min
Anti-CD19 monoclonal antibodies for the treatment of DLBCL
During the Lymphoma Hub Steering Committee meeting, Grzegorz Nowakowski, the Mayo Clinic, Rochester, US, chaired a discussion on anti-CD19 monoclonal antibodies for the treatment of DLBCL. This discus...
8 Heinä 202526min
CELMoDs for the treatment of non-Hodgkin lymphoma
During the Lymphoma Hub Steering Committee Meeting, Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US, chaired a discussion on cereblon E3 ligase modulators (CELMoDs) for the treatme...
3 Heinä 202528min
